Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.75 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.75 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532171 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22533153 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL20767229 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532168 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-12-12 | — | — | US | claimed |
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | claimed |
| WO-2023036960-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2023-03-16 | — | — | WO | claimed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-12-12 | — | — | US | disclosed |
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-118265522-A | Lipid-based RNA formulations suitable for treatment | 生物技术欧洲股份公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKSCI INC. (CA) | 2024-05-21 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2095118-B1 | METHOD OF PREDICTING PHOSPHOLIPIDOSIS INDUCING PROPERTIES OF A SUBSTANCE | KINNUNEN PAAVO (FI) | 2011-03-02 | — | — | EP | disclosed |
| US-20100311844-A1 | Spontaneously Forming Ellipsoidal Phospholipid Unilamellar Vesicles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-09 | — | — | US | disclosed |
| WO-2010126319-A2 | LIPOPEPTIDE WITH SPECIFIC AFFINITY TO THE FC REGION OF AN ANTIBODY, AND ANTIGEN-RECOGNIZING LIPID NANOPARTICLE COMPRISING SAME | 고려대학교 산학협력단 (KR) | 2010-11-04 | — | — | WO | disclosed |
| US-20100204457-A1 | PREPARATION OF ANNEXIN DERIVATIVES | SNIP HOLDINGS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010053489-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2081552-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | Children's Hospital Medical Center (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2020988-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008051818-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007127439-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | P2RY10 1962/4885GPR34 2267/4885GPR174 1670/4885 |
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | P2RY10 1701/4885GPR34 2636/4885GPR174 3460/4885 |
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIK3CA | P2RY10 1342/4885GPR34 2649/4885GPR174 2632/4885 |
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | PHOSPHO1, PLIN3, SARNP | P2RY10 4300/4885GPR34 4287/4885GPR174 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.